AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update.
作者信息
Caraceni Paolo, Angeli Paolo, Prati Daniele, Bernardi Mauro, Berti Pierluigi, Bennardello Francesco, Fiorin Francesco, Piccoli Pierluigi
机构信息
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Department of Medicine, University of Padua, Padua, Italy.
出版信息
Blood Transfus. 2021 Jan;19(1):9-13. doi: 10.2450/2020.0414-20. Epub 2020 Dec 18.
Abstract
摘要
相似文献
1
AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update.意大利肝病研究学会-意大利重症监护医学学会关于肝硬化患者白蛋白合理使用的立场文件：2020年更新版
Blood Transfus. 2021 Jan;19(1):9-13. doi: 10.2450/2020.0414-20. Epub 2020 Dec 18.
2
AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.AISF-SIMTI立场文件：肝硬化患者白蛋白的合理使用
Blood Transfus. 2016 Jan;14(1):8-22. doi: 10.2450/2016.0294-15.
3
AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis.意大利肝脏研究和移植学会-意大利重症监护和移植学会立场文件：肝硬化患者白蛋白的合理使用
Dig Liver Dis. 2016 Jan;48(1):4-15. doi: 10.1016/j.dld.2015.11.008.
4
Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites.长期给予人血白蛋白可改善肝硬化伴难治性腹水患者的生存率。
Liver Int. 2019 Jan;39(1):98-105. doi: 10.1111/liv.13968. Epub 2018 Oct 8.
5
New Insights About Albumin and Liver Disease.白蛋白与肝脏疾病的新认识
Ann Hepatol. 2018;17(4):547-560. doi: 10.5604/01.3001.0012.0916.
6
Pro: The Role of Albumin in Pre-Liver Transplant Management.正方：白蛋白在肝移植前管理中的作用。
Liver Transpl. 2019 Jan;25(1):128-134. doi: 10.1002/lt.25356.
7
Albumin: Indications in chronic liver disease.白蛋白：在慢性肝病中的适应证。
United European Gastroenterol J. 2020 Jun;8(5):528-535. doi: 10.1177/2050640620910339. Epub 2020 Feb 26.
8
The use of human albumin in patients with cirrhosis: a European survey.肝硬化患者中白蛋白的使用：一项欧洲调查。
Expert Rev Gastroenterol Hepatol. 2018 Jun;12(6):625-632. doi: 10.1080/17474124.2018.1460203. Epub 2018 Apr 4.
9
Assessment of prognostic performance of Albumin-Bilirubin, Child-Pugh, and Model for End-stage Liver Disease scores in patients with liver cirrhosis complicated with acute upper gastrointestinal bleeding.肝硬化合并急性上消化道出血患者白蛋白-胆红素、Child-Pugh评分及终末期肝病模型评分的预后性能评估
Eur J Gastroenterol Hepatol. 2018 Jun;30(6):652-658. doi: 10.1097/MEG.0000000000001087.
10
Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis.输注白蛋白可能会降低肝硬化患者显性肝性脑病的发生率和严重程度。
Aging (Albany NY). 2019 Oct 8;11(19):8502-8525. doi: 10.18632/aging.102335.
引用本文的文献
1
Efficacy of albumin use in decompensated cirrhosis and real-world adoption in Australia.白蛋白在失代偿期肝硬化中的疗效及在澳大利亚的实际应用情况。
JGH Open. 2024 Sep 18;8(9):e70029. doi: 10.1002/jgh3.70029. eCollection 2024 Sep.
2
The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis.经颈静脉肝内门体分流术在失代偿期肝硬化患者腹水管理中的作用
J Clin Med. 2024 Feb 27;13(5):1349. doi: 10.3390/jcm13051349.
3
Use of Intravenous Albumin: A Guideline From the International Collaboration for Transfusion Medicine Guidelines.静脉注射白蛋白的使用：来自国际输血医学指南协作的指南。
Chest. 2024 Aug;166(2):321-338. doi: 10.1016/j.chest.2024.02.049. Epub 2024 Mar 4.
4
Use of albumin infusion for cirrhosis-related complications: An international position statement.白蛋白输注在肝硬化相关并发症中的应用：一项国际立场声明。
JHEP Rep. 2023 May 5;5(8):100785. doi: 10.1016/j.jhepr.2023.100785. eCollection 2023 Aug.
5
Evidence-based hyponatremia management in liver disease.基于证据的肝脏疾病低钠血症管理。
Clin Mol Hepatol. 2023 Oct;29(4):924-944. doi: 10.3350/cmh.2023.0090. Epub 2023 Jun 5.
6
Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.日本一项回顾性观察研究：无细胞浓缩腹水回输治疗肝硬化难治性腹水患者凝血和纤溶因子的变化。
In Vivo. 2023 May-Jun;37(3):1226-1235. doi: 10.21873/invivo.13199.
7
Human Albumin Infusion for the Management of Liver Cirrhosis and Its Complications: An Overview of Major Findings from Meta-analyses.人血白蛋白输注治疗肝硬化及其并发症：荟萃分析主要结果概述
Adv Ther. 2023 Apr;40(4):1494-1529. doi: 10.1007/s12325-023-02430-3. Epub 2023 Jan 25.
8
Use of Human Albumin Administration for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis.人血白蛋白在肝硬化患者低钠血症防治中的应用：一项系统评价和Meta分析
J Clin Med. 2022 Oct 8;11(19):5928. doi: 10.3390/jcm11195928.
9
Update on the Evaluation and Management of Portal Hypertension.门静脉高压症评估与管理的最新进展
Gastroenterol Hepatol (N Y). 2021 Dec;17(12):569-578.
10
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications.失代偿期肝硬化患者有效白蛋白的测定：临床和预后意义。
Hepatology. 2021 Oct;74(4):2058-2073. doi: 10.1002/hep.31798. Epub 2021 May 26.
本文引用的文献
1
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.治疗中血清白蛋白水平可指导无并发症肝硬化腹水患者的长期治疗。
J Hepatol. 2021 Feb;74(2):340-349. doi: 10.1016/j.jhep.2020.08.021. Epub 2020 Aug 24.
2
Albumin in decompensated cirrhosis: new concepts and perspectives.失代偿期肝硬化中的白蛋白：新概念和新视角。
Gut. 2020 Jun;69(6):1127-1138. doi: 10.1136/gutjnl-2019-318843. Epub 2020 Feb 26.
3
Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis.白蛋白治疗对失代偿期肝硬化患者全身及门脉血液动力学和全身炎症的影响。
Gastroenterology. 2019 Jul;157(1):149-162. doi: 10.1053/j.gastro.2019.03.021. Epub 2019 Mar 22.
4
Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites.长期给予人血白蛋白可改善肝硬化伴难治性腹水患者的生存率。
Liver Int. 2019 Jan;39(1):98-105. doi: 10.1111/liv.13968. Epub 2018 Oct 8.
5
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.米多君和白蛋白预防肝硬化等待肝移植患者并发症的随机安慰剂对照试验。
J Hepatol. 2018 Dec;69(6):1250-1259. doi: 10.1016/j.jhep.2018.08.006. Epub 2018 Aug 21.
6
Novel perspectives in the management of decompensated cirrhosis.失代偿期肝硬化管理的新视角。
Nat Rev Gastroenterol Hepatol. 2018 Dec;15(12):753-764. doi: 10.1038/s41575-018-0045-2.
7
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.失代偿期肝硬化患者长期白蛋白治疗（ANSWER）：一项开放标签随机试验。
Lancet. 2018 Jun 16;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7. Epub 2018 Jun 1.
8
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.欧洲肝脏研究学会失代偿期肝硬化患者管理临床实践指南
J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10.
9
The Therapeutic use of human albumin in cancer patients' management.人血白蛋白在癌症患者治疗中的应用。
Crit Rev Oncol Hematol. 2017 Dec;120:203-209. doi: 10.1016/j.critrevonc.2017.11.008. Epub 2017 Nov 20.
10
Where does the Albumin go? Human Albumin Solution usage following the implementation of a demand management programme.
Transfus Med. 2017 Jun;27(3):192-199. doi: 10.1111/tme.12406. Epub 2017 Apr 3.
Zotero 插件